

CURRICULUM VITAE

NAME: **Chinazo O. Cunningham, MD, MS**

ADDRESS: Albert Einstein College of Medicine
Montefiore Medical Center
Division of General Internal Medicine
111 E. 210th Street
Bronx, NY 10467
Phone: 718-920-5971
Fax: 718-561-5165
Email: ccunning@montefiore.org

EDUCATION

1986 - 1990	Bachelor of Arts, Psychology	Northwestern University, Evanston, IL
1990 - 1994	Doctor of Medicine	University of California, San Francisco
2006 - 2008	Master of Science (Clinical Research Methods)	Yeshiva University, Albert Einstein College of Medicine Bronx, NY

POST-GRADUATE TRAINING

1994 - 1995	Intern, Primary Care Internal Medicine Residency Program University of California, San Francisco (San Francisco General Hospital)
1995 - 1997	Residency, Primary Care Internal Medicine Residency Program, New York University
1997 - 1998	Chief Resident, Internal Medicine Categorical Residency Program, New York University

ACADEMIC APPOINTMENTS

1998 - 1999	Clinical Instructor of Medicine, Albert Einstein College of Medicine
1999 - 2002	Instructor of Medicine, Albert Einstein College of Medicine
2002 - 2004	Assistant Clinical Professor of Medicine, Albert Einstein College of Medicine
2004 - 2008	Assistant Professor of Medicine, Family & Social Medicine, Albert Einstein College of Medicine
2008 - 2014	Associate Professor of Medicine, Family & Social Medicine, Albert Einstein College of Medicine
2014 – current	Professor of Medicine, Family & Social Medicine, Albert Einstein College of Medicine
2013 – current	Associate Chief, Director of Research Resources, Division of General Internal Medicine, Albert Einstein College of Medicine
2013 – current	Director, General Medicine Fellowship Program, Albert Einstein College of Medicine
2013 – current	Director of Diversity Affairs, Department of Medicine, Albert Einstein College of Medicine

OTHER APPOINTMENTS

1998 - current	Faculty, Internal Medicine Primary Care and Social Medicine Residency Programs, Montefiore Medical Center
2001 - 2003	HIV Site Director, Comprehensive Health Care Center, Montefiore Medical Group
2002 - 2005	Director, Homeless Medicine Course, Albert Einstein College of Medicine
2000 - 2009	Founder and Director, CitiWide/Montefiore Health Services Programs Montefiore Medical Center in collaboration with CitiWide Harm Reduction, Inc
2017 – current	Co-Director, Development Core, Einstein-Rockefeller-CUNY Center for AIDS Research

BOARD CERTIFICATION

1996	New York State Medical License Registration
1997	American Board of Internal Medicine Certificate (recertified in 2008)
2012	American Board of Addiction Medicine Certificate

PROFESSIONAL SOCIETY MEMBERSHIP

Society of General Internal Medicine
Association for Medical Education and Research in Substance Abuse
American Society of Addiction Medicine

AWARDS AND HONORS

1986-1990	Four-year full ride athletic (softball) scholarship to Northwestern University, All-Big Ten, Big Ten Freshman of the Year, Big Ten Batting Champion, Academic All-American
2000	Larry Linn Award, Society of General Internal Medicine

2001 - 2004 Mary O'Flaherty Horn Scholar, Society of General Internal Medicine
2007, 2012 Top manuscript reviewer, Annals of Internal Medicine
2008 Featured in Agency for Healthcare Research and Quality's (AHRQ) Health Care Innovations Exchange
2009 Inducted into Northwestern University Athletic Hall of Fame
2010 Best Program and Curricula Abstract Award, Annual Conference of the Association for Medical Education and Research in Substance Abuse
2012 David E. Roger's Faculty Workshop Award (top 3 workshops at SGIM's national conference)
2015 W. Anderson Spickard, Jr Excellence in Mentorship Award from the Association of Medical Education and Research in Substance Abuse
2015 Clinical Science Mentor of the Year, Albert Einstein College of Medicine
2017 NY State Department of Health Commissioner's Special Recognition Award

OTHER PROFESSIONAL ACTIVITIES

2002 - 2003 Consultant, Health and Disability Working Group, Boston University School of Public Health. Developed national training curriculum for AIDS Educational Training Centers on HIV and Substance Abuse
2004 - current Core Faculty, International AIDS Society – USA
2005 Consultant, New York State AIDS Institute. Reviewed guidelines on HIV and substance abuse
2005 - 2012 Ad Hoc Committee Member, Behavioral and Social Consequences HIV/AIDS Scientific Review Group, NIH
2006 Ad Hoc Committee Member, Study Section reviewing grant applications for program announcement on HIV, drug use, and incarceration, Centers for Disease Control and Prevention
2007 Consultant, NIH, CDC, and HRSA. Provided consultation at the Research Consultation to Address HIV Intervention Strategies for HIV/AIDS Prevention among African Americans
2007 Consultant, HRSA. Provided consultation at the Interventions to Enhance Retention in HIV Primary Care Meeting
2008 Grant reviewer, American Foundations for AIDS Research (amfAR)
2008 Expert Panelist, Substance Abuse and Mental Health Services Administration, Targeted Capacity Expansion for Substance Abuse Treatment and HIV/AIDS
2008 - 2011 Buprenorphine Mentor, New York City Department of Health and Mental Hygiene
2008 - 2015 Consultant, New York State Department of Health, AIDS Institute
2009 - 2011 Vice Chair, New York State Department of Health, AIDS Institute, Substance Use Guideline Committee
2010 - 2015 Member, Racial and Ethnic Populations Committee of the NIH Office of AIDS Research
2011 - 2012 Advisory Committee, National In+Care Campaign, HRSA & National Quality Center
2012 Member, Scientific Advisory Committee, [HIV] Treatment as Prevention Workshop, Vancouver, Canada
2012 - current Chair, New York State Department of Health, AIDS Institute, Substance Use Guideline Committee
2012 - 2016 Member, Data Safety Monitoring Board, NIDA Clinical Trials Network, Project HOPE (#0049)
2012 - 2018 Member, Behavioral and Social Consequences HIV/AIDS Scientific Review Group, NIH
2013 - current Consultant, New York City Department of Health and Mental Hygiene
2013 - 2015 Diversity Steering Committee, Association of Medical Education & Research in Substance Abuse
2014 - 2015 Fellow, Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program for Women, Drexel University
2014 - 2015 Member, American Society of Addiction Medicine's National Practice Guideline Committee for the Use of Medications in the Treatment of Addiction Involving Opioid Use
2016 Member, Opioid Guideline Workgroup, Centers for Disease Control and Prevention's Guideline for Prescribing Opioids for Chronic Pain, 2016
2016 Member, New York City Mayor's Ad-Hoc Heroin and Prescription Opioid Public Awareness Task Force
2016 - current Member, Buprenorphine Steering Committee, New York City Department of Health and Mental Hygiene
2016 - 2018 Chair, Behavioral and Social Consequences HIV/AIDS Scientific Review Group, NIH
2016 – current Member, Buprenorphine Advisory Committee, New York State Department of Health, AIDS Institute, Office of Drug User Health
2017 - current Member, Bronx District Attorney's Heroin Enforcement and Access to Treatment Working Group
2017 - 2018 Member, Staten Island Borough President's Office Opioid Data Working Group
2018 – current Member, Greater NY Hospital Association Opioid Advisory Group
2018 - current Member, NYC Municipal Drug Strategy Council - Community Services Board Substance Misuse Subcommittee

- 2018 - current Member, Governor Cuomo's Workgroup to Draft Legislation for Regulated Adult-Use Marijuana Program
- 2018 – current Member, CDC's National Opioid Prescribing Estimates Workgroup
- 2018 – current Member, Board of Scientific Counselors, National Center for Injury Prevention and Control of the CDC
- 2018 – current Member, National Academy of Science, Engineering, and Medicine's Committee on Medication-Assisted Treatment for Opioid Use Disorder

REVIEWER

PEER-REVIEWED JOURNALS

Addiction, Addiction Science and Clinical Practice, AIDS, AIDS and Behavior, AIDS Care AIDS Patient Care and STDs, American Journal of Public Health, Annals of Internal Medicine, Clinical Infectious Disease, Drug and Alcohol Dependence, Harm Reduction Journal, Journal of AIDS, Journal of Addiction Medicine, Journal of American Medical Association, Journal of Behavioral Medicine, Journal of General Internal Medicine, Journal of Health Care for the Poor and Underserved, Journal of Substance Abuse Treatment, Medical Care, Substance Abuse

CONFERENCE SUBMISSIONS

- 2003 General Medicine Abstracts, Society of General Internal Medicine Annual Meeting
- 2004 Special Populations Abstracts, Society of General Internal Medicine Annual Meeting
- 2004 Scientific Abstracts, Harm Reduction Conference
- 2005 Health Disparities Abstracts, Society of General Internal Medicine Annual Meeting
- 2005 Scientific Abstracts, International Conference on Urban Health
- 2006 Chair, Academic-Community Partnership Workshops, Society of General Internal Medicine Annual Meeting
- 2007-2014 Scientific Abstracts, Society of General Internal Medicine Annual Meeting
- 2010, 2013 Co-Chair, Health Disparities Abstracts, Society of General Internal Medicine Annual Meeting
- 2010 Best Published Paper Committee, Society of General Internal Medicine Annual Meeting
- 2011 Lawrence Linn Award Committee, Society of General Internal Medicine Annual Meeting
- 2016 Horn Award Committee, Society of General Internal Medicine Annual Meeting

PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES

- 1998 - current Attending Physician, Medical Service, Department of Medicine, Montefiore Medical Center
3 residents, 2 students; 4-8 weeks/yr
- 1998 - current Attending Physician, Comprehensive Health Care Clinic, Montefiore Medical Group
- 1998 - 2006 Clinic Preceptor, Comprehensive Health Care Center, Montefiore Medical Group

TEACHING EXPERIENCE

- 1998 - 2002 Core Faculty, Primary Care and Social Medicine Internal Medicine Residency Programs
Extensive teaching of entire 3-year Primary Care and Social Medicine Residency curriculum for 30 residents averaging 35 hours/week.
- 2002 - 2005 Director, Homeless Medicine 4th Year Elective Course, Albert Einstein College of Medicine
- 2003 - current Faculty, Primary Care and Social Medicine Internal Medicine Residency Programs
Teaching typically consists of 2-3 hours per month, focusing on substance use.

COMMITTEES

- 1998 - current Primary Care and Social Medicine Residency Programs Admissions Committee, Montefiore
- 1999 - 2001 Community Services Task Force, Montefiore Medical Center
- 2001 - 2004 Personal-Professional Balance Task Force, Society of General Internal Medicine
- 2004 - 2008 Advisory Committee, All of Us: Documentary Film, Pureland Pictures
- 2006 - 2008 Mentoring Committee, Albert Einstein College of Medicine
- 2007 - current Quality of Care Advisory Committee, New York State Department of Health AIDS Institute
- 2008 - current Chair, Diversity Affairs Committee, Department of Medicine, Albert Einstein College of Medicine
- 2009 - 2010 Promotions Committee, Albert Einstein College of medicine
- 2009 - 2011 Society of General Internal Medicine, (national) Research Committee
- 2010 - 2011 Chair, Best Paper Award Committee, Society of General Internal Medicine
- 2012 - 2013 Member, Larry Linn Award Committee, Society of General Internal Medicine
- 2016 Search committee, Chair of the Department of Psychiatry, Montefiore/Einstein

GRANTS

Current Grants

- 11/18 – 10/21 Laura and John Arnold Foundation
Project Title: Does medical cannabis reduce opioid use in adults with pain: A randomized controlled trial.
Project funding: \$2,000,000
Role: Principal Investigator
- 9/18 - 9/23 AHRQ K12HS026396
Project Title: The center of excellence in promoting LHS operations and research at Einstein/Montefiore (EXPLORE)
Project funding: \$3,332,000
Role: Multiple Principal Investigator (other MPIs: M. McKee, M. Rinke)
- 9/17 – 8/22 NIDA K23DA044327
Project Title: Developing and pilot testing an intervention to increase opioid tapering in primary care
Project funding: \$995,000
Role: Co-Mentor (PI: H. Perez)
- 9/17 – 8/19 NIDA, K99DA043011
Project Title: Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants Living with Hepatitis C-The HCV-ACCELERATE Trial
Project funding: \$370,000
Role: Co-Mentor (PI: M. Akiyama)
- 9/17 – 8/22 NIMH, K23MH114752
Project Title: Minimizing losses from HIV care under universal treatment in Rwanda
Project funding: \$995,000
Role: Co-Mentor (PI: J. Ross)
- 7/17 – 6/22 NIDA, R01DA044878
Project Title: Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk
Project funding: \$3,500,000
Role: Co-Investigator (PI: A. Fox)
- 7/17 – 6/22 NIDA, R01DA044171
Project Title: Does medical cannabis reduce opioid analgesics in HIV+ and HIV- adults with pain?
Project funding: \$3,845,000
Role: Principal Investigator
- 5/17 – 4/22 NIAID, P30AI124414
Project Title: Center for AIDS Research, Developmental Core
Project funding: \$4,173,000
Role: Associate Director, Development Core (PI: H. Goldstein)
- 6/16 – 5/19 NIDA, R03DA039727
Project Title: Resilience in HIV-infected drug users
Project funding: \$167,000
Role: Principal Investigator
- 4/16 – 3/19 Public Health Solutions (NYC Department of Health and Mental Hygiene) 16-BUP-165
Project Title: Expanding access to buprenorphine treatment in primary care
Project funding: \$450,000
Role: Principal Investigator
- 9/15 – 8/20 HRSA, HIV/AIDS Bureau, Special Projects of National Significance. U90HA29236
Project Title: Dissemination of evidence-informed interventions to improve health outcomes along the HIV care continuum - Dissemination and Evaluation Center

Total funding \$2,500,000
Role: Co-Investigator (PI: J. Fox)

- 9/15 – 7/19 NIDA, R01DA039046
Project Title: Prescription opioid use, misuse, disorders and HIV outcomes
Project funding: \$2,309,000
Role: Co-Investigator (PI: J. Starrels)
- 9/15 – 8/20 NIDA, K23DA039060
Project Title: Adaptation and testing of a primary care HCV group medical treatment intervention
Project funding: \$923,000
Role: Mentor (PI: B. Norton)
- 9/15 – 9/20 NIMH, K23MH106386
Project Title: TestED!: Applying implementation science to improve an HIV testing strategy for Emergency Departments
Project funding: \$911,520
Role: Primary Mentor (PI: U. Felsen)
- 4/14 – 3/19 NIDA, K24DA036955
Project Title: Mentoring researchers in drug abuse and HIV
Project funding: \$929,120
Role: Principal Investigator

Completed Grants

- 8/17 – 10/18 NIDA, K08DA043050
Project Title: Leveraging the electronic health record to reduce opioid analgesic prescriptions
Project funding: \$996,000
Role: Primary Mentor (PI: M. Bachhuber)
- 5/17 – 10/18 CDC, U01PS005111
Project Title: Development and pilot testing of a PrEP mobile outreach intervention for women
Project funding: \$649,000
Role: Mentor/Co-Investigator (PI: O. Blackstock)
- 8/13 -7/18 NIDA, R01DA036445
Project Title: A trial of positively smoke free group therapy for HIV-infected smokers
Total funding: \$3,870,000
Role: Co-Investigator (PI: J Shuter)
- 3/14 – 2/18 NIMH, K23MH102129
Project Title: Development and Testing of an Adherence Intervention for HIV+ Women of Color
Project funding: \$923,670
Role: Primary Mentor (PI: O. Blackstock)
- 4/15 – 3/18 NIDA, R34DA039041
Project Title: Buprenorphine group medical visits for drug users at risk for HIV
Project funding: \$751,500
Role: Co-Investigator (PI: A. Fox)
- 2/16 – 1/18 HRSA, 3 H80 CS00626-15-2
Project Title: Substance Abuse Expansion Grant
Project funding: \$650,000
Role: Co- Principal Investigator
- 9/14 – 6/19 Parent Grant: NIH, NIGMS, NIMHD, U54 GM119023/MD009479
Parent Grant Title: National research mentoring network for a diverse biomedical workforce
- 9/15 – 8/17 Pilot Study: Northeast evidence-based mentoring training consortium
Pilot study funding: \$200,000

Role: Co-Investigator (Parent Grant PI: Burgess; Pilot Study PI: Strelnick)

- 8/12 – 6/17 NIDA, R01DA032552
Project Title: Neurocognitive effects of opiate agonist treatment in HIV-infected drug users
Total funding: \$3,541,610
Role: Co-Investigator (PI: J. Arnsten)
- 7/12 – 6/17 NIDA, K23DA034541
Project Title: Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates
Total funding: \$912,980
Role: Primary Mentor (PI: A Fox)
- 5/07 - 4/17 NIDA, R25DA023021
Project Title: HIV and Substance Abuse Clinical Addiction Research and Education Program
Total direct funding: \$2,414,000
Role: Mentor/Co-Investigator (PI: J. Arnsten)
- 7/11 – 4/17 NIDA, R01DA032110
Project Title: Abstinence reinforcing contingency management to suppress HIV viral load
Total funding: \$3,833,749
Role: Principal Investigator
- 9/10 - 8/15 NIDA, K23DA027719
Project Title: Intervention to Promote Opioid Treatment Agreements in Primary Care
Total funding: \$908,734
Role: Primary Mentor (PI: J. Starrels)
- 9/09 – 8/14 HRSA, HIV/AIDS Bureau, Special Projects of National Significance. H97HA15152
Project Title: The Center for Evaluation and Technical Assistance for HIV Women of Color
Total funding \$2,500,000
Role: Co-Investigator (PI: A. Blank)
- 4/11-3/13 Albert Einstein College of Medicine, Center for AIDS Research
Potential Role in Improving Engagement in Care and Medication Adherence
Total funding: \$37,500
Role: Primary Mentor (PI: O. Blackstock)
- 3/11 – 2/14 NIDA, R34DA031066
Project Title: Development of community-based buprenorphine treatment
Total Funding: \$716,876
Role: Principal Investigator
- 4/11-3/13 Albert Einstein College of Medicine, Center for AIDS Research
Project Title: Drug treatment outcomes and HIV risk behaviors among opioid dependent former inmates in a primary care based buprenorphine treatment program
Total funding: \$37,500
Role: Primary Mentor (PI: A. Fox)
- 9/10 – 8/12 NIMH, F31MH093264
Project Title: HIV Care Utilization: A theory-based approach to retention in care
Total funding: \$65,818
Role: Co-Mentor (PI: L. Smith)
- 5/09 – 2/12 NIDA, P20DA026149
Project Title: Pilot Proteomics Center on Drug Abuse HIV/AIDS
Project 3 Title: Neurocognitive Effects of Buprenorphine Among HIV+ Opioid Users
Total direct funding for Project 3: \$606,000
Role: Co-Investigator (PI: R. Angeletti; Project 3 PI: J. Arnsten)

- 9/09 – 9/11 Albert Einstein College of Medicine, Institute for Clinical and Translational Research
Project Title: Community-based buprenorphine inductions
Total funding: \$120,000
Role: Principal Investigator
- 7/06 – 6/10 Robert Wood Johnson Foundation - Harold Amos Medical Faculty Development Award
Project Title: Knowledge, attitudes and barriers to opioid addiction treatment with buprenorphine
Total Funding: \$365,400
Role: Principal Investigator
- 9/04 – 8/10 HRSA, HIV/AIDS Bureau, Special Projects of National Significance, H97HA03793
Project Title: The Development and Evaluation of Integration of Buprenorphine into HIV
Primary Care in Bronx Community Health Centers
Total funding \$1,500,000
Role: Principal Investigator
- 1/09 – 6/09 New York City Department of Health and Mental Hygiene, 09SA027400R0X00
Project Title: Buprenorphine induction in a Bronx community health center
Total Funding: \$100,000/year
Role: Principle Investigator
- 9/06 - 8/09 Centers for Disease Control and Prevention, 5U22PS000551
Project Title: SGIM HIV Prevention Project
Total Funding: \$245,632
Role: Consultant (PI: J. Sosman)
- 9/07 - 8/09 Robert Wood Johnson Foundation – Substance Abuse Policy and Research Program
Project Title: Cost-effectiveness of buprenorphine treatment for opioid dependence
Total Funding: \$100,000
Role: Consultant (PI: B. Schackman)
- 3/07 – 2/09 Ryan White Care Act, Title I - Medical Health and Research Association, 07-HRR-748
Project Title: Harm Reduction, Recovery and Readiness: Providing medical outreach in SRO hotels
Total funding: \$300,000 for subcontract
Role: Director, subcontract under CitiWide Harm Reduction (PI: D. Heller)
- 3/07 – 2/09 Ryan White Care Act, Title I - Medical Health and Research Association, 07-MIC-748
Project Title: Maintenance in Care: Providing medical care in a syringe exchange program
Total funding: \$100,000 for subcontract
Role: Director, subcontract under CitiWide Harm Reduction (PI: D. Heller)
- 10/05 – 2/09 SAMHSA – Substance Abuse, HIV and Hepatitis Prevention for Minority Populations and
Minority Reentry Populations in Communities of Color, U79SP13352-01
Project Title: South Bronx Substance Abuse Prevention, Hepatitis, and HIV Integration Project for
Minority and Minority Reentry Populations in the South and Central Bronx.
Total funding: \$400,000 for subcontract
Role: Site Principal Investigator. (PI: I. Weisfuse)
- 10/03 – 9/06 Centers for Disease Control and Prevention, Minority HIV/AIDS Research Initiative, U65/CCU223363
Project Title: Determinants of Engagement in HIV Primary Care Services among Black
and Hispanic Single Room Occupancy Hotel Residents in New York City
Total funding \$900,000
Role: Principal Investigator
- 10/03 – 9/06 HRSA, HIV/AIDS Bureau, Special Projects of National Significance, #2H97HA00247
Project Title: Evaluation of an Outreach and Intervention Program to Reach HIV-Positive Persons
Living in Bronx, NY Single Room Occupancy Hotels
Total funding \$1,200,000
Role: Principal Investigator

- 7/03 – 2/07 Minority AIDS Initiative, Ryan White Title I, 03-HRC-748
Harm Reduction and Emergency Room Assessment Teams
Funding \$200,000 for subcontract
Role: Director, subcontract under CitiWide Harm Reduction
- 8/00 – 7/07 Medical Health and Research Association, Ryan White Title I, 00-OMS-165
Providing Out-stationed Medical Care Teams in Single Room Occupancy Hotel Rooms
Funding \$2,100,000
Role: Principal Investigator
- 5/01- 6/04 Mary O’Flaherty Horn Scholar Grant – Society of General Internal Medicine
Presented to one junior to mid-level faculty member in the country to recognize and promote
successful balance of personal, professional and social responsibilities.
Total funding \$112,500
Role: Principal Investigator
- 10/01- 9/03 HRSA, HIV/AIDS Bureau, Special Projects of National Significance, H97HA00247
Project Title: Evaluation of an Outreach and Intervention Program to Reach HIV-Positive Persons
Living in Bronx, NY Single Room Occupancy Hotels
Total funding \$400,000
Role: Principal Investigator
- 5/00-5/02 Lawrence Linn Award/Grant - Society of General Internal Medicine
Presented to one junior faculty member in the country to study and improve the lives of HIV+ individuals.
Total funding \$5,000.
Role: Principal Investigator

INVITED PRESENTATIONS

LOCAL

1. Invited Speaker, Einstein’s Social Medicine Lecture Series, The opioid epidemic: How did we get here? How do we move forward? Bronx, NY. January 2018.
2. Invited Speaker, Montefiore Hudson Valley Collaborative, Innovations in integrating substance use treatment into primary care. Tarrytown, NY. January 2018.
3. Invited Speaker, Montefiore Medical Center & Albert Einstein College of Medicine, Department of Medicine Grand Rounds, The Opioid Epidemic: From Pain Management to Addiction Treatment. Bronx, NY. March 2017.
4. Invited Speaker, Montefiore Medical Center, Quality Committee, Opioid Prescribing and Opioid Use Disorder in Primary Care. Bronx, NY. February 2017.
5. Invited Speaker, Montefiore Medical Center & Albert Einstein College of Medicine, AIDS Center and Center for AIDS Research Grand Rounds, Financial Incentives for Substance Abuse and HIV. Bronx, NY. July 2012.
6. Invited Speaker, Montefiore Medical Center & Albert Einstein College of Medicine, Ambulatory HIV Program Grand Rounds, Contingency Management for Substance Abuse and HIV. Bronx, NY. June 2012.
7. Key Note Speaker, Albert Einstein College of Medicine Clinical Training Research Program Commencement. Bronx, NY. June 2012
8. Invited Speaker, Albert Einstein College of Medicine, Division of Substance Abuse Grand Rounds, Contingency Management for Substance Abuse and HIV. Bronx, NY. March 2012.
9. Invited Speaker, Albert Einstein College of Medicine, HIV Prevention, Diagnosis and Treatment: A Best Practices Symposium. HIV Testing Models in Non-Traditional Settings. Bronx, NY. June 2010.

10. Invited Speaker, Montefiore Medical Center, HIV Grand Rounds. Opioid Addiction Treatment: New Opportunities with Buprenorphine. Bronx, NY October 2009.
11. Invited Speaker, Albert Einstein College of Medicine and Montefiore Medical Center Department of Medicine Grand Rounds. Opioid Addiction Treatment: New Opportunities with Buprenorphine. Bronx, NY. September 2009.
12. Invited Speaker, Albert Einstein College of Medicine. The Physician as Advocate for Social Change. Bronx, NY. February 2008
13. Invited Speaker, Montefiore Medical Center Palliative Care Grand Rounds. HIV and Substance Abuse: Treatment Strategies. Bronx, NY. June 2006.
14. Invited Speaker, Albert Einstein College of Medicine, Community Council Forum, Bronx Center to Reduce & Eliminate Ethnic & Racial Health Disparities. Practicing Out of the Box: The Research Challenges of Caring for HIV-Infected Substance Users. Bronx, NY. May 2006
15. Invited Speaker, Albert Einstein College of Medicine, Overcoming Health Disparities: The Challenging Landscape. HIV/AIDS and Harm Reduction. New York, NY. May 2006.

REGIONAL

1. Invited Speaker and Panelist, New York University: Controversies in Population Health: What will it take to mitigate the opioid epidemic? New York, NY. October 2018.
2. Invited Speaker, Community Health Care Association of New York State's Behavioral Health Summit, "Addressing opioid use disorder in primary care," White Plains, NY. October 2018.
3. Invited Speaker and Panelist, Mount Sinai Medical Center, The Role of Primary Care in Addressing the Opioid Crisis in New York State. New York, NY. September 2018.
4. Invited Speaker, Lincoln Hospital Medicine Grand Rounds, "The Opioid Epidemic: Where Do We Go From Here?" Bronx, NY. August 2018.
5. Invited Speaker, Community Health Care Association of New York State's Opioid Summit. Common Concerns about Integrating Buprenorphine Treatment into Primary Care. Albany, NY. June 2018.
6. Invited Panelist, Healthy New York: How Affordable Care, Disease, & Addiction, and Mental Health Impact New York's Health Care Policies. New York, NY. April 2018.
7. Invited Speaker, 2017 Population Health Summit, Addressing the Opioid Epidemic Using Clinical and Non-Traditional Population Health Strategies. New York, NY. December 2017.
8. Invited Speaker, NYC DOHMH, Buprenorphine Learning Community. Queens, NY. June 2017.
9. Invited Speaker, Wyckoff Hospital Internal Medicine Grand Rounds. The Opioid Epidemic: How did we get here? Where do we go from here? Brooklyn, NY. May 23, 2017.
10. Invited Speaker, International AIDS Society-USA, Opioids and HIV Infection: From Pain Management to Addiction Treatment. New York, NY. February 2017.
11. Invited Speaker, Student National Medical Association Northeast Regional Conference. Research Careers in Academic Medicine. Bronx, NY. November 2016.
12. Invited Speaker, Student National Medical Association Northeast Regional Conference. Women in Academic Medicine. Bronx, NY. November 2016.
13. Invited Speaker, New York City Mayor's Ad-Hoc Heroin and Prescription Opioid Public Awareness Task Force. Buprenorphine for the Treatment of Opioid Dependence. Bronx, NY. March 2016.

14. Invited Speaker, Jacobi Medical Center, Department of Medicine Grand Rounds. The Opioid Epidemic: Why It Matters for HIV. Bronx, NY. January 2016
15. Invited Speaker, In+Care National Campaign. Retaining HIV+ Drug Users. National webinar. July 2012.
16. Invited Speaker, HIV Qual, NYS DOH Quarterly Conferences. Exploring the 1–Visit Patient. Manhattan, NY. June 2012.
17. Invited Speaker, Hudson Year 400 Urban Health Conference. Closing the Gap for Marginalized Populations. Manhattan, NY. September 2009.
18. Invited Speaker, HIV Grand Rounds, St. Lukes-Roosevelt Medical Center. Manhattan, NY. April 2009.
19. Invited Speaker, New York City Department of Health and Mental Hygiene, HIV Planning Counsel. Manhattan, NY. April 2009.
20. Invited Speaker, Nassau University Medical Center. HIV and Substance Abuse. East Meadow, NY. April 2007.
21. Invited Speaker, Nassau University Medical Center, HIV Annual Symposium 2005. HIV and Substance Abuse. Uniondale, NY. May 2005.
22. Invited Speaker, New York/New Jersey AIDS Education Training Center, Caring for HIV-Infected Substance Users. Bronx, NY. October 2004.

NATIONAL

1. Invited Panelist, Bloomberg American Health Summit 2018, State and City Action to Achieve National Impact on Overdose. Washinton, DC. November 2018.
2. Invited Speaker, ID Week 2018, Approach to Managing Opioid Addiction in HIV. San Fransisco, CA. October 2018.
3. Invited Speaker and Panelist, International Drug Policy Reform Conference, Vivitrol: Wonder drug or shot in the dark? Atlanta, GA. October 2017.
4. Invited Speaker, International AIDS Society-USA, Opioids and HIV Infection: From Pain Management to Addiction Treatment. Atlanta, GA. March 2017.
5. Invited Speaker, Fenway Institute. Opioids and HIV: From pain management to addiction treatment. Boston, MA. October 2016.
6. Invited Speaker, 2016 National Ryan White Conference on HIV Care and Treatment, Opioids and HIV: From pain management to addiction treatment. Washington, DC. August 2016.
7. Invited Speaker, Student National Medical Association National Conference. Career Opportunities for Physicians Interested in Research. Austin, TX. March 2016.
8. Invited Speaker, George Washington University School of Public Health. The Opioid Epidemic: Why It Matters for HIV. Washington, DC. March 2016.
9. Invited Speaker, Plenary Discussion, Strategies to Improve the HCV Continuum of Care: Best Practices in Testing, Linkage to Care, & Treatment. 2015 National Summit on HCV and HIV Diagnosis, Prevention and Access to Care. Arlington, VA. June 2015.
10. Invited Speaker, HIV Treatment and Prevention among Drug Users in the Bronx: My Journey. Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention. Atlanta, GA. February 2013.

11. Invited Speaker, Workshop on Mixed Methods in Research, Society of General Internal Medicine Annual Meeting, Orlando, FL. May 2012
12. Invited Speaker, Workshop on Part-Time Careers in General Internal Medicine, Society of General Internal Medicine Annual Meeting, Orlando, FL. May 2012
13. Invited Speaker, Workshop on Buprenorphine Treatment in Community Health Centers. Annual Conference of the National Association of Community Health Centers, Community Health Institute and Expo. Dallas, TX. September 2010.
14. Invited Speaker, University of North Carolina. HIV Care 2010. New Opioid Addiction Treatment Opportunities with Buprenorphine. Chapel Hill, NC. May 2010
15. Invited Speaker, University of North Carolina. HIV Care 2010. Delivering HIV Care Out of the Box. Chapel Hill, NC. May 2010
16. Invited Speaker, Workshop on Case Management for Marginalized Populations, Society of General Internal Medicine 29th Annual Meeting, Los Angeles, CA. April 2006
17. Invited Speaker, NIMH/IAPAC International Conference on HIV Treatment Adherence. Conducting research with HIV-infected substance users: A community perspective. Jersey City, NJ. March 2006
18. Invited Speaker, Centers for Disease Control and Prevention, National Institute of Health. Treatment and Management of HIV Infection in the U.S. Conference. Strategies in Caring for Marginalized Populations. Atlanta, GA. September 2005.
19. Keynote Speaker, University of North Carolina. HIV Care 2005: Antiretroviral Therapy, Hepatitis B/C, Addiction and Adherence. Addiction and Antiretroviral Therapy: Diagnosis and Treatment of Addicted Patients. Chapel Hill, NC. May 2005.
20. Invited Speaker and Workshop, International AIDS Society-USA, HIV and Substance Abuse. New York, NY. October 2004.
21. Invited Speaker, Boston University School of Public Health, Outreach Workers Conference. Treatment Update: HIV and Substance Abuse. Boston, MA. September 2004.
22. Invited Speaker and Workshop, International AIDS Society-USA, HIV and Substance Abuse, and Workshop on Secondary Prevention Aimed at Substance Users. Washington DC. August 2004.
23. Invited Speaker, Texas HIV Connection, Annual Street Outreach Conference, Workshop on HIV and Substance Abuse. Austin, TX. June 2004.
24. Invited Speaker, University of North Carolina. Antiretroviral Therapy, Hepatitis B/C, Hyperlipidemia, and Changing Behavior: HIV Care 2004. HIV-Infected Substance Users: Treatment Strategies. Chapel Hill, NC. May 2004.
25. Invited Panelist, Health Resources and Services Administration, Centers for Disease Control and Prevention, Conference on Engaging and Retaining HIV-Infected Individuals. Washington DC. February 2004
26. Invited Speaker, Texas HIV Connection, Annual Street Outreach Conference, Workshop on Substance Abuse and HIV-Related Issues. Austin, TX. June 2003.

27. Invited Speaker, University of North Carolina. Antiretroviral Therapy, Hepatitis C, Opportunistic Infections, Depression and Substance Abuse: HIV Care 2003. Crack: Diagnosis and Treatment. Chapel Hill, NC. May 2003.
28. Key Note Speaker and Workshop, Health Resources Service Administration, Boston University School of Public Health, AIDS Educational Training Centers. Kaleidoscope of Care: National Training Model to Care for HIV-Infected Substance Users. San Antonio, TX. January 2003.
29. Invited Speaker, Workshop on Caring for the Substance Using Patient, Society of General Internal Medicine 25th Annual Meeting, Atlanta, GA. May 2002

INTERNATIONAL

1. Invited Speaker. “The Opioid Epidemic: The View from Primary Care” Havana, Cuba. October 2018.
2. Key Note Speaker, British Columbia Center on Substance Use Addiction Research Day. The Opioid Epidemic: Where do we go from here? An American Perspective. Vancouver, Canada. May 2018.
3. Invited Speaker, Hudson Year 400 Urban Health Conference. Sketches from the Bronx, What We See and What We Do. Amsterdam, the Netherlands. April 2009
4. Invited Speaker, Public Health Providers Quarterly Educational Conference. Strategies to Improve Access to and Coordination of Care. Amsterdam, the Netherlands. April 2009
5. Invited Speaker, NIMH/IAPAC International Conference on HIV Treatment Adherence. Strategies to improve HIV health care utilization among marginalized populations. Jersey City, NJ. March 2007

MEDIA COVERAGE

2018 Interviewed by the Washington Post, “How Republicans pivoted from the war on drugs to cutting prison sentences” on December 19, 2018 at https://www.washingtonpost.com/national/how-republicans-pivoted-from-the-war-on-drugs-to-cutting-prison-sentences/2018/12/19/61846d04-0383-11e9-9122-82e98f91ee6f_story.html?utm_term=.de1e175d0af9

Interviewed by JAMA, “States move to substitute opioids with medical marijuana to quell epidemic” on December 18, 2018 at http://images.burrellesluce.com/image/5807B/5807B_15361

Interviewed by National Public Radio, “Is America Ready for Prescription Heroin?” on December 6, 2018 at <https://www.npr.org/sections/health-shots/2018/12/06/673986164/is-america-ready-for-prescription-heroin>

Panelist and interviewed by The Atlantic, “Cancer vs. People” on November 14, 2018 at <http://peoplevcancer.theatlantic.com/>

Interviewed by the Washington Post, “Trump signs sweeping opioid bill. Expect to hear about it on the campaign trail” on October 24, 2018 at https://www.washingtonpost.com/politics/trump-signs-sweeping-opioid-bill-expect-to-hear-about-it-on-the-campaign-trail/2018/10/24/1328598c-d7a9-11e8-aeb7-ddcad4a0a54e_story.html?utm_term=.f138f6a10d5b

Panelist and interviewed by The Atlantic, “Combating a Crisis: Opioids in America” on October 4, 2018 at <http://combatingacrisis.theatlantic.com/>

Market Watch, “National Recognition for Einstein Montefiore Addiction Specialist” on Sept 21, 2018 at <https://www.marketwatch.com/press-release/national-recognition-for-einstein-montefiore-addiction-specialist-2018-09-21>

Interviewed by the Philadelphia Inquirer, “Could marijuana help treat opioid addiction? Pennsylvania may soon find out” on July 6, 2018 at <http://www.philly.com/philly/health/addiction/could-marijuana-be-the-answer-to-the-opioid-epidemic-pa-may-soon-find-out-20180706.html>

Interviewed by WHYY’s (Philadelphia Public Radio) The Pulse, “Lessons from Vancouver: US cities consider safe injection facilities” on July 5, 2018 at <https://whyy.org/segments/lessons-from-vancouver-u-s-cities-consider-supervised-injection-facilities/>

Quoted by Yahoo News, “Suboxone recognized as new first line of treatment for opioid substitution therapy” on May 24, 2018 at https://www.doximity.com/doc_news/v2/entries/12470058

Interviewed by the Canadian Broadcasting Company (CBC) Radio The Early Edition with Stephen Quinn on May 15, 2018 at <http://www.cbc.ca/listen/shows/the-early-edition/episode/15544569>.

Interviewed by Kaiser Health News, “Medical Marijuana’s ‘Catch 22’: Federal limits on research hinder patients’ relief on April 12, 2018 at <https://khn.org/news/medical-marijuanas-catch-22-fed-limits-on-research-hinder-patients-relief/>

Interviewed by Nashville Public Radio, “Tennessee weighs one argument for medical cannabis—could it cut opioid use?” on March 21, 2018 at <http://nashvillepublicradio.org/post/tennessee-weighs-one-argument-medical-cannabis-could-it-cut-opioid-use#stream/0>

Interviewed by New York Times in “Opioid Addiction Knows No Color, but Its Treatment Does” on January 12, 2018 at https://www.nytimes.com/2018/01/12/nyregion/opioid-addiction-knows-no-color-but-its-treatment-does.html?_r=1

Interviewed by WBUR (Boston Public Radio), “Latinos are hit especially hard by the opioid epidemic in Mass. But why?” on May 3, 2018 at <http://www.wbur.org/commonhealth/2018/05/03/latino-opioid-overdose-deaths>

Interviewed by Rolling Stone Magazine, “Opioid and pot: Inside the fight for real research” on May 2, 2018 at <https://www.rollingstone.com/culture/features/opioids-pot-inside-fight-real-research-w519728>

Panelist at Washington Post’s Addiction in America: On the front lines – Boston, on February 22, 2018. https://www.washingtonpost.com/post-live-2018-addiction-in-america-boston/?utm_term=.f025f21387ac

Study featured in Consultant 360, “Cannabis could reduce opioid use in HIV patients” on January 18, 2018 at <https://www.consultant360.com/exclusives/cannabis-could-reduce-opioid-use-hiv-patients>

2017 Interviewed by NBC News, “How the Opioid Crisis Affects People of Color” on December 16, 2017 at <https://www.nbcnewyork.com/on-air/as-seen-on/How-the-Opioids-Crisis-Affects-People-of-Color-New-York-464501103.html>

Interviewed by STAT News, “FDA approves Indivior’s monthly injection to treat opioid addiction” on November 30, 2017 at <https://www.statnews.com/2017/11/30/fda-indivior-opioid-treatment/>

Interviewed by CNN.com in “Opioid Commission’s anti-marijuana argument stirs anger” on November 13, 2017 at <http://edition.cnn.com/2017/11/13/health/marijuana-opioid-commission/index.html>.

Quoted and study highlighted in New Jersey 101.5 FM’s podcast “Marijuana vs. opioids—one is illegal, the other is killing us” on November 4, 2017 at <http://edition.cnn.com/2017/11/13/health/marijuana-opioid-commission/index.html>

Interviewed by New York Times in “The Bronx’s Quest, Brutal War with Opioids” on October 12, 2017 at https://www.nytimes.com/2017/10/12/nyregion/bronx-heroin-fentanyl-opioid-overdoses.html?_r=0

Interviewed by the ACP Internist in “Primary care takes on opioid addiction” on October 2017 at <https://acpinternist.org/archives/2017/10/primary-care-takes-on-opioid-addiction.htm>

Interviewed by the ACP Hospitalist in “Hospitalist involvement needed to treat opioid epidemic” on October 2017 at <https://acphospitalist.org/archives/2017/10/hospitalist-treat-opioid-epidemic.htm>

Featured in STAT News, “Can Marijuana Wean the Nation Off Opioids? This Doctor Wants to Know.” On September 29, 2017 at <https://www.statnews.com/2017/09/29/marijuana-opioid-research/>

Quoted in Cato Policy Report, “The Myth of an Opioid Prescription Crisis” on September/October 2017 at <https://www.cato.org/policy-report/septemberoctober-2017/myth-opioid-prescription-crisis>

Featured in Market Watch, “A government health agency is funding the first ever study on medical marijuana’s impact on opioid abuse” on August 23, 2017 at <http://www.marketwatch.com/story/a-government-health-agency-is-funding-the-first-ever-study-on-medical-marijuanas-impact-on-opioid-abuse-2017-08-11>

Study highlighted in Politico Health Care, Grant Land, on August 9, 2017.

Featured in Crain’s Health Pulse, “Montefiore to study cannabis for chronic pain” on August 9, 2017.

Featured on Albert Einstein College of Medicine website’s home page, “First long-term study on medical marijuana’s impact on opioid use for pain” on August 9, 2017 at <http://www.einstein.yu.edu/news/releases/1260/first-long-term-study-on-medical-marijuanas-impact-on-opioid-use-for-pain/>

Featured and aired on The Pulse, “Stigma keeps some doctors from treating drug addiction” on August 3, 2017 on WHYY-FM and <http://www.newsworks.org/index.php/thepulse/item/105013-stigma-keeps-some-doctors-from-treating-drug-addiction>

Op-Ed in Syracuse.com, “Katko-Rice bill on synthetic opioids ‘throws gasoline on the fire’” on June 23, 2017 at <http://www.syracuse.com/opinion/index.ssf/2017/06/katko-rice-bill-cracking-down-on-synthetic-opioids-wont-solve-crisis-commentary.html>

Featured in Einstein Magazine, Winter/Spring 2017, “Breaking the Chains of Addiction” on June 19, 2017 at <http://magazine.einstein.yu.edu/winterspring-2017/>

Featured by Albert Einstein College of Medicine in “Einstein and Montefiore on the Forefront of Addiction” on June 20, 2017 at <https://www.youtube.com/user/EinsteinCollegeofMed>

Featured on The Fix podcast by Ground Truth, “Chapter 4 – A Better Way to Treat Addiction” on May 25, 2017 at <http://thegroundtruthproject.org/projects/the-fix-groundtruth-podcast/>

Interviewed by NY Daily News, “Changing tactics, NYPD focuses on help for drug users, not prison” on May 23, 2017. Available at <http://www.nydailynews.com/new-york/changing-tactics-nypd-focuses-drug-users-not-prison-article-1.3181986>

Interviewed by Crain’s Health Pulse, “Montefiore struggles to fund study on cannabis and opioids” on January 30, 2017.

2016 Interviewed by Crain’s, “Docs, drug-policy advocates push back on one piece of plan to tackle opioid epidemic” on June 16, 2016, at http://www.crainsnewyork.com/article/20160616/HEALTH_CARE/160619888

- Blog featured in Alternet, entitled “Addiction didn’t kill Prince; Stigma about addiction did” on June 3, 2016, at <http://www.alternet.org/drugs/addiction-stigma-kill-prince>.
- Interviewed by the Los Angeles Times, “Prince’s death casts spotlight on anti-opioid addiction drug” on May 30, 2016, at <http://www.latimes.com/entertainment/music/la-et-ms-prince-death-opioid-suboxone-20160524-snap-story.html>.
- Blog featured on the Doctor’s Tablet entitled “Our bittersweet path to dealing with opioid addiction” on April 28, 2016 at <http://blogs.einstein.yu.edu/our-bittersweet-path-to-dealing-with-opioid-addiction/>
- Op-Ed in the Huffington Post, “Controversy over CDC guideline reflects a fractured field” on April 18, 2016 at http://www.huffingtonpost.com/albert-einstein-college-of-medicine/controversy-over-cdc-opio_b_9705246.html.
- Interviewed by New York Times in “Bronx needle exchange, once dismissed, finds acceptance” on April 17, 2016 at <http://www.nytimes.com/2016/04/18/nyregion/bronx-needle-exchange-once-dismissed-finds-acceptance.html>.
- Interviewed by Forbes in “Clean safe places to heroin addicts to shoot up: Coming to a city near you?” on March 30, 2016 at <http://www.forbes.com/sites/ritarubin/2016/03/30/clean-safe-places-for-heroin-addicts-to-shoot-up-coming-to-a-city-near-you/#4ca982923382>
- Op-ed in the Times Union “Help drug addicts by getting bureaucracy out of the way” on March 29, 2016 at <http://www.timesunion.com/tuplus-opinion/article/Help-drug-addicts-by-getting-bureaucracy-out-of-7213469.php>
- Interviewed by the Washington Post “Overdoses on anti-anxiety meds such as Valium and Xanax are on the Rise” on February 22, 2016 at https://www.washingtonpost.com/national/health-science/overdoses-on-anti-anxiety-meds-such-valium-and-xanax-are-on-the-rise/2016/02/22/4f6a6d8e-d727-11e5-be55-2cc3c1e4b76b_story.html
- Interviewed by STAT news, “More than just an opioid crisis: Deaths from anti- anxiety drugs are on the rise, too” on February 20, 2016 at <http://www.statnews.com/2016/02/18/benzodiazepines-overdose-deaths/>
- Interviewed by LiveScience, “Deaths from benzo sedatives quietly increasing” on February 20, 2016 at <http://www.livescience.com/53774-benzodiazepines-overdose-deaths-increasing.html>.
- Interviewed by Daily Mail (UK) “American’s hidden drug epidemic: Overdose deaths from sedatives including Xanax and valium soar, experts warn” on February 18, 2016, at <http://www.dailymail.co.uk/health/article-3453509/America-s-hidden-drug-epidemic-Overdose-deaths-sedatives-including-Xanax-Valium-soar-experts-warn.html>
- 2015 Blog featured on the Doctor’s Tablet entitled “Ending the silence on heroin overdose deaths” on August 6, 2015 at <http://blogs.einstein.yu.edu/ending-the-silence-on-heroin-overdose-deaths/>
- Blog featured on the Doctor’s Tablet entitled “Opioid addiction treatment options” on February 19, 2015 at <http://blogs.einstein.yu.edu/opioid-addiction-treatment-options/>
- 2014 Interviewed by Forbes “How to prevent rising controlled substance use in Medicare” on December 22, 201, at <http://www.forbes.com/sites/cjarlotta/2014/12/22/how-to-prevent-rising-controlled-substance-use-in-medicare/3/>
- Interviewed and filmed by CBS News, “Dying for pain relief in the opioid epidemic” on October 10, 2014 at <http://www.cbsnews.com/news/14days-dying-for-pain-relief-opioid-abuse/>

Study featured in the New York Times article “Of Pot and Percocet” on August 30, 2014. Available at http://www.nytimes.com/2014/08/31/opinion/sunday/of-pot-and-percocet.html?_r=0

Interviewed for WNYC’s All Things Considered and on-line news “City Sees Climb in Fatal Heroin Overdoses” on August 28, 2014. Available at <http://www.wnyc.org/story/city-sees-climb-fatal-heroin-overdoses/on>.

- 2013 Op-ed in the Huffington Post, “New York Times Misses Mark on Buprenorphine Drug”, November 22, 2013. Available at http://www.huffingtonpost.com/aaron-fox/buprenorphine-new-york-times_b_4324656.html
- 2010 Research findings featured in Alcohol, Other Drugs, and Health: Current Evidence, sponsored by NIDA, NIAAA, Boston Medical Center, and Boston University Medical Campus. March-April 2010.
- 2008 Featured/photographed in Northwestern University Magazine, “Lifesaver to New York’s Forgotten.” Fall 2008, at <http://www.northwestern.edu/magazine/fall2008/alumninews/wherearetheynow/watn.html>
- 2007 Featured in Agency for Healthcare Research and Quality’s (AHRQ) Health Care Innovations Exchange. “Medical Outreach to HIV Patients in Unstable Housing Increases Use of Care and HIV-Related Medications and Improves Patient Perceptions of Quality.” Available at <http://www.innovations.ahrq.gov/content.aspx?id=2088>
- Featured and photographed in Housing Works AIDS Issue Update, “Do-Good Doc”. May 11, 2007. Available at http://www.hwupdate.org/update/2007/05/dogood_doc.html
- 2004 Featured and photographed in JAMA news article: Trubo R. CDC initiative targets HIV research gaps in black and Hispanic communities. JAMA. 2004 Dec 1;292(21):2563-4.
- 2003 Featured on Bronx News, Channel 12. Interviewed about medical marijuana. Feb 2003.
- 2001 Featured in the ACP-ASIM Observer news article: Strategies to balance training, your personal life. July 2001. Available at <http://www.acponline.org/journals/news/jul01/balance.htm>.

PUBLICATIONS

PEER-REVIEWED ORIGINAL RESEARCH

1. **Cunningham CO**, Shapiro S, Berg K, Sacajiu G, Paccione G, Goulet JL. An Evaluation of a Medical Outreach Program Targeting Unstably Housed HIV-Infected Individuals. J Health Care Poor Underserved. 2005 Feb;16(1):127-138.
2. **Cunningham CO**, Sohler NL, McCoy K, Heller D, Selwyn PA. Health Care Access and Utilization Patterns in Unstably Housed HIV-Infected Individuals in New York City. AIDS Patient Care STDS. 2005 Oct;19(10):690-5.
3. **Cunningham CO**, Drucker E, Meissner P, McCoy K, Selwyn PA. The perceived need for buprenorphine treatment at a primary care clinic in the South Bronx: A market survey. Addict Disord Their Treatment. 2005 Dec;4(4):125-126.
4. **Cunningham CO**, Sohler NL, McCoy K, Kunins HV. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006 May;38(5):336-40.
5. **Cunningham CO**, Sohler NL, Berg KM, Shapiro S, Heller D. Type of substance use and access to HIV-related health care. AIDS Patient Care STDS. 2006;20(6):9-17.
6. Cunningham WE, Sohler NL, Tobias C, Drainoni ML, Bradford J, Davis C, Cabral HJ, **Cunningham CO**, Eldred L, Wong MD. Health Services Utilization for People with HIV Infection: A Comparison of a Population Targeted for Outreach with the U.S. Population in Care. Medical Care. 2006 Nov;44(11):1038-1047.

7. **Cunningham CO**, Sohler NL, Korin L, Gao W, Anastos K. HIV status, trust in health care providers, and distrust in the health care system among Bronx women. *AIDS Care*. 2007 Feb;19(2):226-234.
8. **Cunningham CO**, Sohler NL, Ramsey K, Li X. A comparison of HIV-related utilization measures in a marginalized population: Self-report versus medical record information. *Medical Care*. 2007 Mar;45(3):264-268.
9. **Cunningham CO**, Sohler NL, Wong MD, Relf M, Cunningham WE, Drainoni ML, Bradford J, Pounds M, Cabral H. Utilization of Health Care Services in HIV-Infected Marginalized Populations Enrolled in Outreach Programs. *AIDS Patient Care STDs*. 2007;21(3):177-186.
10. Sacajiu G, Fox A, Ramos M, Sohler N, Heller D, **Cunningham C**. The evolution of HIV illness representation among marginally housed persons. *AIDS Care*. 2007 Apr;19(4):539-545.
11. Sohler NL, Li X, **Cunningham CO**. Perceived discrimination and patient ratings of the HIV health care system and their providers. *Public Health Rep*. 2007;122(3):347-355. PMC1847497
12. Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, **Cunningham CO**. Type and pattern of illicit drug use and access to health care services for HIV-infected people. *AIDS Patient Care STDs*. 2007 Jun;21(S1):S68-76.
13. Cabral HJ, Tobias C, Rajabiun S, Sohler NL, **Cunningham CO**, Wong MD, Cunningham WE. Outreach program contacts: Do they increase the likelihood of engagement and retention in HIV primary care for hard-to-reach patients? *AIDS Patient Care STDs*. 2007 Jun;21(S1):S59-S56.
14. Tobias CR, Cunningham W, Cabral HD, **Cunningham CO**, Eldred L, Naar-King S, Bradford J, Sohler NL, Wong MD, Drainoni ML. Living with HIV but without medical care: barriers to engagement. *AIDS Patient Care STDS*. 2007 Jun;21(6):426-34.
15. **Cunningham CO**, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to Obtaining Waivers to Prescribe Buprenorphine for Opioid Addiction Treatment Among HIV Physicians. *J Gen Intern Med*. 2007 Sep;22(9):1325-9. Epub 2007 Jul 10. PMC2219773
16. **Cunningham CO**, Sanchez JP, Heller D, Sohler NL. Assessment of a medical outreach program to improve access to HIV care among marginalized individuals. *Am J Public Health*. 2007 Oct;97(10):1758-61. Epub 2007 Aug 29. PMC1994196
17. Sohler NL, Lindsay R, Fitzpatrick L, Anastos K, **Cunningham CO**. Does Patient-Provider Racial/Ethnicity Concordance Influence Ratings of Trust Among People with HIV Infection? *AIDS Behav*. 2007 Nov;11(6):884-96. Epub 2007 Mar 10.
18. Roose RJ, Kunins HV, Sohler NL, Elam RT, **Cunningham CO**. Nurse practitioner and physician assistant interest in prescribing buprenorphine. *J Subst Abuse Treat*. 2008 Jun;34(4):456-9. Epub 2007 Jul 30. PMC2486415
19. **Cunningham CO**, Sanchez JP, Li X, Heller D, Sohler NL. Medical and supportive service utilization in a medical program targeting marginalized HIV-infected individuals. *J Health Care Poor Underserved*. 2008 Aug;19(3):981-990. PMC2705623
20. **Cunningham CO**, Giovanniello A, Sacajiu G, Whitley S, Mund P, Beil R, Sohler NL. Buprenorphine treatment in an urban community health center: What to expect. *Fam Med*. 2008 Jul-Aug;40(7):500-6. PMC2840630
21. Roose RJ, **Cunningham CO**. What is the best management for a patient with a percutaneous occupational exposure to HIV? *Evidence-Based Practice*. 2008 August;11(8):4-5.

22. Roose RJ, Hayashi AS, **Cunningham CO**. Self-management of injection-related wounds among injection drug users in Washington, D.C. *J Addict Dis*. 2009;28(1):74–80. PMC2695510.
23. Netherland J, Botsko M, Egan JE, Saxon AJ, **Cunningham CO**, Finkelstein R, Gourevitch MN, Renner JA, Sohler N, Sullivan LE, Weiss L, Fiellin DA and the BHIVES Collaborative. Factors affecting willingness to provide buprenorphine treatment. *J Subst Abuse Treat*. 2009;36(3):244-251. PMC2866292
24. **Cunningham CO**, Giovanniello A, Sacajiu G, Li X, Brisbane M, Sohler NL. Inquiries about and initiation of buprenorphine treatment in an inner-city health center. *Subst Abuse*. 2009 Jul-Sep;30(3):261-2. PMC2746741
25. **Cunningham CO**, Doran B, DeLuca J, Dyksterhouse R, Asgary R, Sacajiu G. Routine opt-out HIV testing in an urban community health center. *AIDS Patient Care STDS*. 2009 Aug;23(8):619-23. PMC2832648
26. Sohler NL, Li X, **Cunningham CO**. Gender disparities in HIV healthcare utilization among the severely disadvantaged: Can we determine the reasons? *AIDS Patient Care STDS*. 2009 Sep;23(9):775-83. PMC2859765
27. Kunins HV, Sohler NL, Roose RJ, **Cunningham CO**. HIV provider endorsement of primary care buprenorphine treatment: A vignette study. *Fam Med* 2009;41(10):722-8. PMC2827924
28. Sohler NL, Coleman S, Cabral H, Naar-King S, Tobias C, **Cunningham CO**. Does self-report data on HIV primary care utilization agree with medical record data for socially marginalized populations in the U.S.? *AIDS Patient Care STDS*. 2009 Oct;23(10):837-43. PMC2859764
29. Sohler NL, Li X, Kunins HV, Sacajiu G, Giovanniello A, Whitley S, **Cunningham CO**. Home- versus office-based buprenorphine inductions for opioid-dependent patients. *J Subst Abuse Treat*. 2010 Mar;38(2):153-9. Epub 2009 Oct 3. PMC2849656
30. Whitley S, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, **Cunningham CO**. Factors associated with complicated buprenorphine inductions. *J Subst Abuse Treat*. 2010 Jul;39(1):51-7. PMC4755478
31. **Cunningham CO**, Sohler NL, Cooperman NA, Berg KM, Litwin AH, Arnsten JH. Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users. *Subst Use Misuse*. 2011;46(2-3):218-32. PMC3150583
32. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthius PT, Flanigan TP, **Cunningham CO**, et al. HIV treatment outcomes among HIV-infected opioid dependent patients receiving buprenorphine/naloxone treatment in HIV care setting: Results from a multi-site study. *J Acquir Immune Defic Syndr*. 2011 Mar 1;56 Suppl 1:S22-32. PMC3263431
33. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman L, Chaudhry A, **Cunningham CO**, et al. Drug treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone. *J Acquir Immune Defic Syndr*. 2011 Mar 1;56 Suppl 1:S33-8. PMC3863630
34. Sullivan LE, Botsko M, **Cunningham CO**, O'Connor PG, Hersh D, Mitty J, Lum PJ, Schottenfeld RS, Fiellin DA. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. *J Acquir Immune Defic Syndr*. 2011 Mar 1;56 Suppl 1:S54-61. PMC3065971.
35. **Cunningham CO**, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. *J Subst Abuse Treat*. 2011 Jun;40(4):349-56. Epub 2011 Feb 18. PMC3081891.
36. Smith LR, Fischer JD, **Cunningham CO**, Amico KR. Understanding the behavioral determinants of retention in HIV care: A qualitative evaluation of a situated information, motivation, behavioral skills

model of care initiation and maintenance. *AIDS Patient Care STDS*. 2012 Jun;26(6):344-55. Epub 2012 May 21. PMC3366334

37. Cocohoba JM, Althoff KN, Cohen M, Hu H, **Cunningham CO**, Sharma A, Greenblatt RM. Pharmacist counseling in a cohort of women with HIV and women at risk for HIV. *Patient Prefer Adherence*. 2012;6:457-63. Epub 2012 Jun 18. PMC3393123.
38. Starrels JL, Fox AD, Kunins HK, **Cunningham CO**. They don't know what they don't know: Internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. *J Gen Intern Med*. 2012 Nov;27(11):1521-7. PMC3475838
39. Fox AD, Sohler NL, Ning Y, Starrels JL, Giovanniello A, **Cunningham CO**. Pain is not associated with worse office-based buprenorphine treatment outcomes. *Subst Abus*. 2012 Oct;33(4):361-5. PMC3447624
40. Sohler NL, Weiss L, Egan JE, Lopez C, Favaro J, Cordero J, **Cunningham CO**. Consumer attitudes about opioid addiction treatment: A focus group study in New York City. *J Opioid Manag*. 2013 Mar-Apr;9(2):111-9. PMC4012752
41. Bachhuber MA, **Cunningham CO**. Availability of buprenorphine on the Internet for purchase without a prescription. *Drug Alcohol Depend*. 2013 Jun 1;130(1-3):238-40. PMC3600391
42. **Cunningham CO**, Giovanniello A, Kunins HV, Roose RJ, Fox AD, Sohler NL. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. *Am J Addict*. 2013 Jul;22(4):352-7. PMC3694744.
43. **Cunningham CO**, Roose RJ, Starrels JL, Giovanniello A, Sohler NL. Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. *J Addict Med*. 2013 May 29. [Epub ahead of print]. PMC3737355.
44. Kunins HV, Sohler NL, Giovanniello A, Thompson D, **Cunningham CO**. Implementation and evaluation of a buprenorphine education and training program for primary care internal medicine residents. *Subst Abus*. 2013;34(3):242-7. PMC3799907
45. Earnshaw VA, Smith LR, **Cunningham CO**, Copenhaver MM. Intersectionality of Internalized HIV Stigma and Internalized Substance Use Stigma: Implications for Depressive Symptoms among PLWH with a History of Substance Use. *J Health Psychol*. 2015 Aug; 20(8): 1083–1089. PMC4753572
46. Shah P, Sohler NL, Lopez C, Fox AD, **Cunningham CO**. Awareness of, experience with, and attitudes towards buprenorphine among opioid users visiting a New York City syringe exchange program. *J Opioid Manag*. 2013 Nov-Dec; 9(6):407-13. PMC4012750
47. Bachhuber MA, **Cunningham CO**. Changes over time in offering on-site testing for HIV, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. *JAMA*. 2013 Dec 25;310(24):2671-2. PMC4038104
48. Fox AD, Anderson MR, Bartlett G, Valverde J, MacDonald RF, Shapiro LI, **Cunningham CO**. A description of an urban transitions clinic serving formerly incarcerated people. *J Health Care Poor Underserved*. 2014;25(1):376-82. PMC4059495
49. Fox AD, Shah P, Sohler NL, Lopez C, **Cunningham CO**. I heard it from a friend: Assessing interest in buprenorphine treatment. *Subst Abus*. 2014;35(1):74-9. PMC3942801
50. Starrels JL, Wu B, Peyser D, Fox AD, Batchelder A, Barg F, Arnsten JH, **Cunningham CO**. It made my life a little easier: Understanding primary care providers' use of opioid treatment agreements for patients with chronic pain. *J Opioid Manag*. 2014 Mar-Apr;10(2):95-102. PMC3983567

51. **Cunningham CO**, Buck J, Shaw F, Seigal L, Agins B. Factors associated with returning to HIV care after a gap in New York State. *J Acquir Immune Defic Syndr*. 2014 Aug 1;66(4):419-27. PMC4120656
52. Bachhuber MA, Southern WN, **Cunningham CO**. Profiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United States. *Med Care*. 2014 May;52(5):428-34. PMC4277871
53. Felsen UR, Bellin EY, **Cunningham CO**, Zingman BS. Development of an electronic medical record-based algorithm to identify patients with unknown HIV status. *AIDS Care*. 2014 Oct;26(10):1318-25. PMC4095997
54. Nahvi S, Blackstock O, Sohler NL, Thompson D, **Cunningham CO**. Smoking cessation treatment among office-based buprenorphine treatment patients. *J Subst Abuse Treat*. 2014 Aug;47(2):175-9. PMC4104355
55. Fox AD, Andersen MR, Bartlett G, Valverde J, **Cunningham CO**. Health outcomes and retention in care following release from prison for patients of an urban transitions clinic. *J Health Care Poor Underserved*. 2014 Aug;25(3):1139-52. PMC4138598
56. Bachhuber MA, Saloner B, **Cunningham CO**, Barry SL. Medical cannabis laws and opioid pain reliever overdose mortality in the United States, 1999-2010. *JAMA Intern Med*. 2014 Oct;174(10):1668-73. PMC4392651
57. Fox AD, Chamberlain D, Sohler NL, Frost T, **Cunningham CO**. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. *J Subst Abuse Treat*. 2015 Jan;48(1):112-6. PMC4250323
58. Blank AE, Fletcher J, Blackstock O, Verdecias N, **Cunningham CO**. Factors associated with retention and viral suppression among a cohort of HIV+ women of color. *AIDS Patient Care STDS*. 2015 Jan;29 Suppl 1:S27-35. PMC4283067
59. Blackstock O, Blank AE, Fletcher J, Verdecias N, **Cunningham CO**. Considering care-seeking behaviors reveals important differences among HIV-positive women not engaged in care: implications for intervention. *AIDS Patient Care STDS*. 2015 Jan;29 Suppl 1:S20-6. PMC4283072
60. Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, **Cunningham CO**. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. *Addict Sci Clin Pract*. 2015 Jan 16;10(1):2. PMC4410477
61. Blackstock OJ, Haughton LJ, Garner RY, Horvath KJ, Norwood C, **Cunningham CO**. General and health-related Internet use among an urban, community-based sample of HIV-positive women: Implications for intervention development. *AIDS Care*. 2015 Apr;27(4):536-44. PMC4312556
62. Felsen UR, Bellin EY, **Cunningham CO**, Zingman BS. Unknown HIV status in the Emergency Department: Implications for an expanded testing strategy. *J Int Assoc Provid AIDS Care*. 2016 Jul;15(4):313-9. PMC4755924
63. Blackstock OJ, Shah PA, Haughton LJ, Horvath KJ, **Cunningham CO**. HIV-infected women's perspectives on the use of the internet for social support: A potential role for online group-based interventions. *J Assoc Nurses AIDS Care*. 2015 Jul-Aug;26(4):411-9. PMC4439388
64. Fox AD, Chamberlain A, Frost T, **Cunningham CO**. Harm reduction agencies as a potential site for buprenorphine treatment. *Subst Abuse*. 2015;36(2):155-6015. PMC4706457

65. Blackstock OJ, **Cunningham CO**, Haughton L, Norwood C, Garner R, Horvath K. Higher eHealth literacy is associated with HIV risk behaviors among HIV-infected women who use the Internet. *J Assoc Nurses AIDS Care*. 2016 Jan-Feb;27(1):102-8. PMC4695307
66. Fox AD, Masyukova M, **Cunningham CO**. Optimizing psychosocial support during office-based buprenorphine treatment in primary care: patients' experiences and preferences. *Subst Abus*. 2016 Jan-Mar;37(1):70-5. PMC4801741
67. Starrels JA, Haughton L, **Cunningham CO**. When human immunodeficiency virus (HIV) treatment goals conflict with guideline-based opioid prescribing: A qualitative study of HIV treatment providers. *Subst Abus*. 2016 Jan-Mar;37(1):148-53. PMC4859811
68. Maradiaga JA, Nahvi S, Sanchez J, **Cunningham CO**, Fox AD. I kicked the hard way: I got incarcerated. *J Subst Abuse Treat*. 2016 Mar;62:49-54. PMC4888768
69. Felsen UR, **Cunningham CO**, Zingman BS. Increased HIV testing among hospitalized patients who declined testing in the emergency department. *AIDS Care*. 2016 May;28(5):591-7.
70. Glenn MC, Sohler NL, Starrels JL, Maradiaga J, Jost JJ, Arnsten JH, **Cunningham CO**. Characteristics of methadone maintenance treatment patients prescribed opioid analgesics. *Subst Abus*. 2016 Jul-Sep;37(3):387-391. PMC4935628
71. Bachhuber MA, Hennessy S, **Cunningham CO**, Starrels JA. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. *Am J Public Health*. 2016 Apr;106(4):686-8. PMC4816010
72. Smith LR, Earnshaw VA, Copenhaver MM, **Cunningham CO**. Substance Use Stigma: Reliability and validity of a theory-based scale for substance-using populations. *Drug Alcohol Depend*. 2016 May 1;162:34-43. PMC5293183
73. Arias F, Arnsten JH, **Cunningham CO**, Coulehan K, Batchelder A, Brisbane M, Segal K, Rivera-Mindt M. Neurocognitive, psychiatric, substance use characteristics in opioid-dependent adults. *Addict Behav*. 2016 Mar 31;60:137-143.
74. Hawks L, Norton B, **Cunningham CO**, Fox AD. The Hepatitis C Virus cascade at an urban post-incarceration transitions clinic. *J Viral Hepat*. 2016 Jun; 23(6): 473–478. PMC4850086
75. Safo S, **Cunningham CO**, Beckman A, Haughton L, Starrels JL. A place at the table: A qualitative analysis of community board members' experiences with HIV/AIDS research. *BMC Med Res Methodol*. 2016 Jul 11;16:80
76. Safo SA, Blank AE, **Cunningham CO**, Quinlivan EB, Lincoln T, Blackstock OJ. Pain is associated with missed clinic visits among HIV-positive women. *AIDS Behav*. 2017 Jun;21(6):1782-1790. PMC5222730.
77. Riggins DP, Ning Y, **Cunningham CO**, Fox AD. Recent incarceration and buprenorphine maintenance treatment outcomes HIV-positive patients. *Subst Abus*. 2016 Aug 11:1-6. PMC5303565
78. Blackstock OJ, Moore BA, Berkenblit G, Calabrese SK, **Cunningham CO**, Fiellin DA, Patel V, Phillips KA, Tetrault JM, Shah M, Edelman EJ. A cross-sectional online survey of HIV Pre-Exposure Prophylaxis Adoption among Primary Care Physicians. *J Gen Intern Med*. 2017 Jan;32(1):62-70.
79. Doorley SL, Ho CJ, Echeverria E, Preston C, Ngo H, Kamal A, **Cunningham CO**. Buprenorphine Shared Medical Appointments for the Treatment of Opioid Dependence in a Homeless Clinic. *Subst Abus*. 2017 Jan-Mar;38(1):26-30. NIHMSID 901229

80. Ross J, Hanna DB, Felsen UR, **Cunningham CO**, Patel VV. Emerging from the database shadows: characterizing undocumented immigrants in a large cohort of HIV-infected persons. *AIDS Care*. 2017 Mar 27;1-8.
81. Edelman EJ, Moore BA, Berkenblit GV, Calabrese SK, **Cunningham CO**, Fiellin DA, Patel V, Phillips KA, Tetrault JM, Shah M, Blackstock OJ. Primary Care Physicians' Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs. *AIDS Behav*. 2017 Apr;21(4):1025-1033.
82. Nance RM, Delaney JAC, Golin CE, Wechsberg WM, **Cunningham C**, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. *AIDS Care*. 2017 Apr;29(4):464-468.
83. Norton BL, Beiten A, Glenn M, DeLuca J, Litwin AH, **Cunningham CO**. Retention in Buprenorphine Treatment is Associated with Improved HCV Care Outcomes. *J Subst Abuse Treat*. 2017 Apr;75:38-42.
84. Felsen UR, **Cunningham CO**, Heo M, Futterman DC, Weiss JM, Zingman BS. An expanded HIV testing strategy leveraging the electronic medical record uncovers undiagnosed infection among hospitalized patients. *J Acquir Immune Defic Syndr*. 2017 May 1;75(1):27-34. PMC5388580
85. Fox AD, Sohler NL, Frost T, Lopez C, **Cunningham CO**. Development and evaluation of a community-based buprenorphine treatment intervention. *Harm Reduct J*. 2017 May 12;14(1):23.
86. Smith LR, Amico KR, Fisher JD, **Cunningham CO**. 60 Minutes for Health: Examining the feasibility and acceptability of a low-resource behavioral intervention designed to promote retention in HIV care. *AIDS Care*. 2017 Jun 28:1-11.
87. Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, **Cunningham CO**, Johnson N, Laraque F, Litwin AH. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. *Int J Drug Policy*. 2017 Aug 12: (17)30235-9.
88. Ross J, Felsen UR, **Cunningham CO**, Patel VV, Hanna DB. Outcomes along the HIV care continuum among undocumented immigrants in clinical care. *AIDS Res Hum Retroviruses*. 2017 Oct;33(10):1038-1044.
89. Shah P, **Cunningham CO**, Brisbane M, Nahvi SN. Use of pharmacotherapy and electronic cigarettes for smoking cessation among buprenorphine maintained patients. *J Addict Med*. 2017 Nov/Dec;11(6):494-497.
90. Scott TM, Rivera Mindt M, **Cunningham CO**, Arias F, Coulehan K, Massey Z, Mangalonzo A, Olsen P, Arnsten JH. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: A preliminary study. *Subst Abuse Treat Prev Policy*. 2017 Nov 15;12(1):48.
91. Bachhuber MA, O'Grady M, Chung H, Neighbors C, DeLuca J, D'Aloia E, Diaz A, **Cunningham CO**. Delivery of routine screening and brief intervention for unhealthy drinking to adult primary care patients in an urban academic Federally Qualified Health Center. *Addict Sci Clin Pract*. 2017 Dec 7;12(1):33.
92. Sohler NL, Khalid L, Starrels JO, Jost JJ, Arnsten JH, Bachhuber MA, Nahvi S, **Cunningham CO**. Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. *Subst Use Misuse*. 2018 Jan 17:1-6.
93. Bachhuber MA, Arnsten JH, Starrels JL, **Cunningham CO**. Willingness to Participate in Longitudinal Research Among People with Chronic Pain Who Take Medical Cannabis: A Cross-Sectional Survey. *Cannabis Cannabinoid Res*. 2018 Mar 1;3(1):45-53.

94. Matsuzaki M, Quan VM, Gwads M, Delaney JAC, Kuo I, Perez Trejo ME, Cunningham W, **Cunningham CO**, Christopoulos K. Perceptions of access and barriers to care among illicit drug users and hazardous drinkers: findings from the Seek, Test, Treat, and Retain study (STTR). *BMC Public Health*. 2018 Mar 20;18(1):366
95. Buonora M, Perez HR, Heo M, **Cunningham CO**, Starrels JL. Race and gender are associated with opioid dose reduction among patients on chronic opioid therapy. *Pain Med*. 2018 Jul 18. Epub ahead of print.
96. Pacek LR, Copeland J, Dierker L, **Cunningham CO**, Martins SS, Goodwin RD. Among whom is cigarette smoking declining in the United States? The impact of cannabis use status, 2002-2015. *Drug Alcohol Depend*. 2018 Oct 1;191:355-360.
97. Jakubowski A, Castillo F, Pappas A, Isaacsohn L, **Cunningham CO**, Bachhuber MA. Development and evaluation of a pilot overdose education and naloxone distribution program for hospitalized general medical patients. *Subst Abuse*. In press.
98. Kladney M, Joudrey PJ, **Cunningham CO**, Bachhuber MA. Pharmacotherapy prescribing to patients with concurrent tobacco and alcohol use disorder in a large, urban, integrated health system. *J Gen Intern Med*. In press.

OTHER PEER-REVIEWED PUBLICATIONS

99. **Cunningham CO**, Selwyn PA. Mastitis due to *Mycobacterium avium* complex in an HIV-infected woman taking highly active antiretroviral therapy. *AIDS Patient Care STDS* 2003;17(11):547-550.
100. Heller D, McCoy K, **Cunningham C**. An invisible barrier to integrating HIV primary care with harm reduction services: Philosophical clashes between the harm reduction and medical models. *Public Health Rep*. 2004 Jan-Feb;119(1):32-9. PMC1502252
101. Tobias C, Cunningham WE, **Cunningham CO**, Pounds M. Making the connection: The importance of engagement and retention in HIV medical care. *AIDS Patient Care STDs*. 2007 Jun;21(S1):S3-S8.
102. Mund PA, Heller D, Meissner P, Matthews DW, Hill M, **Cunningham CO**. Delivering care out of the box: The evolution of an HIV harm reduction medical program. *J Health Care Poor Underserved*. 2008 Aug;19(3):944-951. PMC2686111
103. Blackstock OJ, Patel VV, **Cunningham CO**. Use of technology for HIV prevention among adolescent and adult women in the United States. *Curr HIV/AIDS Rep*. 2015 Dec;12(4):489-99. PMC4643397
104. Ross J, **Cunningham CO**, Hanna D. HIV outcomes among migrants from low- and middle-income countries living in high-income countries: a review of recent evidence. *Curr Opin Infect Dis*. 2018 Feb;31(1):25-32.
105. Bachhuber MA, Nash D, Souther WN, Heo M, Berger M, Schepis M, **Cunningham CO**. Reducing the default dispense quantity for new opioid analgesic prescriptions: study protocol for a cluster randomized controlled trial. *BMJ Open*. 2018 Apr 20;8(4):e019559
106. Bachhuber MA, Arnsten JH, **Cunningham CO**, Sohler NL. Does medical cannabis use increase or decrease the use of opioid analgesics and other prescription drugs? *J Addict Med*. 2018 Jul/Aug;12(4):259-261.

OTHER PUBLICATIONS IN PEER-REVIEWED JOURNALS

107. Bachhuber MA, **Cunningham CO**. For-profit treatment of opioid addiction. *Health Aff (Millwood)*. 2013 Nov;32(11):2060.
108. Bachhuber MA, Saloner B, **Cunningham CO**, Feingold J, Barry CL. Could Delaware's medical marijuana law reduce harms from opioid analgesics? *Del Med J*. 2014 Nov;86(11):341-3.

109. **Cunningham CO**. Opioid and HIV infection: From pain management to addiction treatment. *Top Antivir Med*. 2017;25(4):143-146.

UNDER REVIEW

110. Edelman EJ, Moore B, Calabrese S, Berkenblit G, **Cunningham CO**, Ogbuagu O, Patel VV, Phillips K, Tetrault J, Shah M, Blackstock O. Preferences for implementation of HIV Pre-Exposure Prophylaxis (PrEP): Results from a survey of primary care providers. Submitted to *AIDS Behav*.
111. Joudrey PJ, Kladney M, **Cunningham CO**, Bachhuber MA. Primary care engagement is associated with increased pharmacotherapy prescribing for alcohol use disorder. Submitted to *Subst Abuse*.
112. Smith LR, Mittal MR, Copenhaver M, **Cunningham CO**, Earnshaw V. Stigma Associated with Receiving Methadone Treatment: Reliability and validity of a theory-based scale for persons with a history of methadone treatment. Submitted to *J Addict Med*.
113. Friedman S, **Cunningham CO**, Haramati L. Having a Primary Care Provider is the Strongest Predictor of Successful Follow-up of Inner-City Patients Enrolled in a Randomized Cardiovascular Trial. Submitted to *J Amer Board Fam Med*.
114. Sohler NL, Slawek D, Earnshaw V, Jost J, Lee A, Mancini J, Mompremier A, **Cunningham CO**. Drug use and HIV medication adherence in people living with HIV who currently use drugs. Submitted to *J Subst Abuse Treat*.

OTHER EDUCATIONALLY RELEVANT PUBLICATIONS

1. **Cunningham C**. Reflections of a Horn Scholar. *Society of General Internal Medicine Forum*. 2003;26(1):1-9.
2. **Cunningham CO**, Selwyn P. HIV-related medical complications and treatment. In: *Substance Abuse: A Comprehensive Textbook*, 4th Edition. Lowinson JH, Ruiz P, Millman RB (editors). Baltimore MD: Williams & Wilkins; 2004.
3. Tuinebreijer W, **Cunningham C**, Sohler N. Urban health: A tale of two cities. In: *The Low Countries, Arts and Society in Flanders and the Netherlands*. Luc Devoldere (editor). Flanders, Belgium; Flemish-Netherlands Association. 2009.
4. Kunins HV, **Cunningham CO**. Assessment of Unhealthy Alcohol Use in Primary Care. In: *Addressing Unhealthy Alcohol Use in Primary Care*. Saitz R (editor). New York, NY: Springer; 2013.
5. Kattan J, Fox AD, **Cunningham CO**, Paone D, Harrison M, Kunins HV. Buprenorphine—an office-based treatment for opioid use disorder. *City Health information*. 2015;34(1):1-8. Available at <http://www.nyc.gov/html/doh/downloads/pdf/chi/chi-34-1.pdf>
6. The American Society of Addiction Medicine's National Practice Guideline for the Use of Medications for the Treatment of Addiction Involving Opioid Use. May 27, 2015. <http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/national-practice-guideline.pdf?sfvrsn=22>
7. Kattan J, Fox AD, **Cunningham CO**, Kunins HV. Addressing alcohol and drug use – an integral part of primary care. *City Health information*. 2016;35(3):21-28. Available at <https://www1.nyc.gov/assets/doh/downloads/pdf/chi/chi-35-3.pdf>

EDUCATIONALLY RELEVANT PUBLICATIONS IN OTHER MEDIA

1. Kunins H, **Cunningham CO**. Treatment of opioid dependence in patients with HIV/AIDS. Available <http://www.iasusa.org/cow/>

2. Darby E, **Cunningham CO**. HIV Webstudy: Special Populations: Heroin and HIV. Available at <http://depts.washington.edu/hivaids/>
3. Darby E, **Cunningham CO**. HIV Webstudy: Special Populations: Methamphetamine Use and HIV. Available at <http://depts.washington.edu/hivaids/>
4. **Cunningham CO**, Kunins H. Current Issues in HIV and Substance Abuse. Available at <http://www.iasusa.org/cow/>